Johnson & Johnson (NYSE:JNJ) Shares Bought by American Money Management LLC

American Money Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 37,404 shares of the company’s stock after purchasing an additional 3,148 shares during the quarter. American Money Management LLC’s holdings in Johnson & Johnson were worth $5,409,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. IFS Advisors LLC grew its holdings in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $32,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Wells Fargo & Company cut their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Raymond James decreased their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Stifel Nicolaus dropped their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Finally, Leerink Partners cut their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Price Performance

JNJ opened at $163.63 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $394.32 billion, a P/E ratio of 24.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company’s 50 day simple moving average is $158.68 and its 200-day simple moving average is $156.13. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm earned $2.29 EPS. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.